RARE - Ultragenyx Pharmaceutical Inc.

24.1
-0.960   -3.983%

Share volume: 1,386,644
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$25.06
-0.96
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 10%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.86%
1 Month
18.89%
3 Months
2.99%
6 Months
-27.28%
1 Year
-32.89%
2 Year
-44.84%
Key data
Stock price
$24.10
P/E Ratio 
0.00
DAY RANGE
$23.95 - $25.22
EPS 
-$5.83
52 WEEK RANGE
$18.29 - $42.37
52 WEEK CHANGE
-$35.41
MARKET CAP 
2.219 B
YIELD 
N/A
SHARES OUTSTANDING 
96.630 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
1.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,658,379
AVERAGE 30 VOLUME 
$1,992,375
Company detail
CEO: Emil D. Kakkis
Region: US
Website: ultragenyx.com
Employees: 1,310
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.

Recent news